Ligand’s Second Quarter Financial Results to be Reported August 3rd

About this update from Ligand Pharmaceuticals Incorporated

[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.\n\n\nSecond Quarter 2020 Earnings Conference Call\n\n\n\n\nWhat:\n\n\n \n\nLigand conference call to discuss financial results and provide general business updates\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n\n\nDate:\n\n\n \n\nMonday, August 3, 2020\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n\n\nTime:\n\n\n \n\n8:30 a.m. Eastern time (5:30 a.m. Pacific time)\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n\n\nConference Call:\n\n\n \n\nDial (833) 325-0071 within the U.S.\n\n\n\n\n\n \n\n\n \n\nDial (720) 405-1612 outside the U.S.\n\n\n\n\n\n \n\n\n \n\nConference ID is 1697855\n\n\n\n\n\n \n\n\n \n\n \n\n\n\n\n\nWebcast:\n\n\n \n\nLive conference call webcast and replay accessible at www.ligand.com\n\n\n\n\n\nAbout Ligand Pharmaceuticals\n\n\nLigand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The Vernalis Design Platform (VDP) integrates protein structure determination and engineering, fragment scre...

More updates from Ligand Pharmaceuticals Incorporated